ArticleClinical case reports2025
Challenges in Diagnosis and Management of Ovarian Neuroendocrine Carcinoma: A Case of Aggressive Disease With Multimodal Treatment Approach.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Challenges in Diagnosis and Management of Ovarian Neuroendocrine Carcinoma: A Case of Aggressive Disease With Multimodal Treatment Approach.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine tumors (NETs) of the ovary are extremely rare, accounting for only 1%-2% of malignant ovarian tumors, with high-grade subtypes demonstrating particularly aggressive behavior. We describe a 47-year-old woman who presented with abdominal swelling, irregular bleeding, and pain, and was diagnosed with high-grade ovarian neuroendocrine carcinoma following surgical resection. Despite initial treatment with paclitaxel and carboplatin, residual disease persisted, prompting therapy with long-acting Sandostatin. The disease subsequently progressed with hepatic and peritoneal involvement, and she was successfully managed with cisplatin and etoposide. This case illustrates the diagnostic complexity and aggressive course of ovarian neuroendocrine carcinoma and underscores the importance of individualized, multimodal treatment strategies and vigilant follow-up in the absence of standardized guidelines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.